Press Release

June 6, 2017

Fresenius Medical Care introduces new pure bicarbonate buffer peritoneal dialysis fluids

Fresenius Medical Care, the world’s largest provider of dialysis products and services, is expanding its peritoneal dialysis (PD) product range with the introduction of two new dialysis fluids. Both products contain pure bicarbonate buffers and have considerably reduced amounts of glucose degradation products (UltraLow GDP). The new fluids – bicaVera® low calcium and bicaNova® – will allow therapy to be adjusted more precisely to the individual patient’s needs in terms of calcium or buffer concentration.

bicaVera® and bicaNova® regulate the acid-base balance through a pure bicarbonate buffer, while the low calcium concentrations in these PD dialysis fluids follow the recent International Society of Peritoneal Dialysis (ISPD) guidelines.

The two new PD fluids were presented this month at the 2017 European Dialysis and Transplantation Association/European Renal Association (ERA-EDTA) congress in Madrid. They will be introduced in steps in several European markets.

In peritoneal dialysis, the lining of a patient’s abdominal cavity – the peritoneum – acts as the filter for cleaning the blood. Of the approximately 3 million dialysis patients around the world, about 350,000 choose peritoneal dialysis treatment.

Fresenius Medical Care offers a wide range of products for Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD). These include
various dialysis fluids, bag systems, cyclers for APD, and the related bag and tube systems.

For medical professionals, more information about the peritoneal dialysis products of Fresenius Medical Care is available at www.freseniusmedicalcare.com/en/healthcare-professionals/peritoneal-dialysis/peritoneal-dialysis-overview/

Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,654 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 310,473 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company’s website at www.freseniusmedicalcare.com.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.